Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study
| Autor: | Heinrich Sauer, Waldemar Greil, Adelheid Czernik, J. Tegeler, W. Ludwig-Mayerhofer, B. Müller-Oerlinghausen, Natalia Erazo, G.A.E. Rudolf, T. Wetterling, Rolf R. Engel, Henner Giedke, Michael Osterheider |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Lithium (medication) Schizoaffective disorder Pharmacology Patient Readmission law.invention Randomized controlled trial Lithium Carbonate law Antimanic Agents Internal medicine medicine Humans Pharmacology (medical) Bipolar disorder Adverse effect Biological Psychiatry Psychiatric Status Rating Scales General Medicine Carbamazepine Middle Aged medicine.disease Survival Analysis Discontinuation Psychiatry and Mental health Treatment Outcome Tolerability Psychotic Disorders Patient Satisfaction Female Psychology medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0940-1334 |
| Popis: | In a randomised multicentre study, the prophylactic efficacy of lithium and carbamazepine was compared in schizoaffective disorder. A total of 90 ICD-9 schizoaffective patients were included in the maintenance phase (2.5 years). They were also diagnosed according to RDC and DSM-III-R and classified into subgroups. Mean serum levels were 0.58 +/- 0.12 mmol/l for lithium and 6.4 +/- 1.5 micrograms/ml for carbamazepine (mean dose 643 +/- 179 mg/d). Outcome criteria were hospitalisation, recurrence, concomitant psychotropic medication and adverse effects leading to discontinuation. There were more non-completers under carbamazepine than under lithium (p = 0.02). Survival analyses demonstrated no significant differences between lithium and carbamazepine in treatment outcome. Patient's ratings of side effects (p = 0.003) and treatment satisfaction (p = 0.02) favoured carbamazepine. Following the RDC criteria, patients of the schizodepressive and non-classifiable type did better under carbamazepine (p = 0.055 for recurrence), whereas in the schizomanic patients equipotency of both drugs was found. Applying DSM-III-R, carbamazepine demonstrated a superiority in the patient group with more schizophrenia-like or depressive disorders (p = 0.040 for recurrence), but not in patients fulfilling the DSM-III-R criteria of bipolar disorder. Lithium and carbamazepine seem to be equipotent alternatives in the maintenance treatment of broadly defined schizoaffective disorders. However, in subgroups with depressive or schizophrenia-like features and regarding its long-term tolerability carbamazepine seems to be superior. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink